Supplemental Data

Meta analysis of variant predictions in congenital adrenal hyperplasia caused by mutations in CYP21A2

Mayara J. Prado[1,2,3,4], Rodrigo Ligabue-Braun[5], Arnaldo Zaha[1,2]‡, Maria Lucia Rosa

Rossetti[1,4]‡, Amit V. Pandey[3,4] ‡

‡These authors contributed equally to this work.

[1]Graduate Program in Cell and Molecular Biology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre CEP 91501-970, Brazil. [2] Center for Biotechnology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre CEP 91501-970, RS, Brazil. [3] Department of Biomedical Research, University of Bern, Bern 3010, Switzerland. [4] Pediatric Endocrinology Unit, Department of Pediatrics, University Children's Hospital Bern, Bern 3010, Switzerland. [5] Department of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre CEP 90050-170, Brazil. [6] Graduate Program in Molecular Biology Applied to Health, Universidade Luterana do Brasil (ULBRA), Canoas CEP 92425-020, Brazil.

ORCiD numbers: M.J.P (0000-0003-0647-4429), R.L-B. (0000-0002-2555-9754), A.Z. (0000-0001-6336-474X), M.L.R.R (0000-0002-9672-9394), and A.V.P (0000-0001-8331-5902).

Table S1. Single predictors selected for performance analysis with *CYP21A2* variants.

Single Predictors	Description	Website	Ref.
CADD	Integrative annotation built based on diverse genomic feature derived from surrounding sequence context, gene model **annotation**, **evolutionary** constraint, **epigenetic** measurements, and **functional** predictions.	https://cadd.gs.washington.edu/	[1]
ConSurf	Algorithm uses phylogenetic relationships among homologous sequences and the specific dynamics of the analyzed sequence with **evolutionary** models to estimate the evolutionary rates of the amino acid of the macromolecules and to map them onto the structure and/or sequence.	https://consurf.tau.ac.il/	[2]
DANN	Deep neural network which takes non-linear relationships among features based on diverse genomic derived from surrounding sequence context, gene model **annotation**, **evolutionary** constraint, **epigenetic** measurements, and **functional** predictions.	https://cbcl.ics.uci.edu/public_data/DANN/	[3]
FATHMM	**Evolutionary** conservation algorithm which uses homologous sequences with species-specific weighting to predict the protein's tolerance to missense variants.	http://fathmm.biocompute.org.uk/	[4]
MAPP	A statistical framework predictor which uses protein **physicochemical** characteristics of each amino acid position on the **evolutionary** variation.	http://mendel.stanford.edu/sidowlab/downloads/MAPP/index.html	[5]
MutPred2	Machine learning-based to predict amino acid substitution through **evolutionary**, **structural,** and **functional** proprieties.	http://mutpred.mutdb.org/	[6]
PANTHER-PSEP	Predict using **evolutionary** preservation data, measuring though the length of time estimation that a site has been preserved.	http://www.pantherdb.org/tools/csnpScoreForm.jsp	[7]
PhD-SNP^g	Machine learning algorithm for predicting SNVs in both non-coding and coding regions through **evolutionary data**.	https://snps.biofold.org/phd-snpg/	[8]
PolyPhen-2	It uses human protein **evolutionary** and **structural** data to predict amino acid substitution effect on the protein stability and functionality.	http://genetics.bwh.harvard.edu/pph2/	[9]
PROVEN	Predict the functional effect through amino acid exchange **evolutionary** data and quality of the neighborhood sequence alignment rather than the target position.	http://provean.jcvi.org/genome_submit_2.php?species=human	[10]
SIFT	Predicts through sequence homology algorithm assuming **evolutionary** conserved regions tend to be less tolerant.	https://sift.bii.a-star.edu.sg/www/SIFT4G_vcf_submit.html	[11]
SNAP2	A neural network method based on machine learning to predict the variant effect in the molecular function through **evolutionary** and **structural** protein data with an amino acid substitution matrix of effect probabilities.	https://rostlab.org/services/snap2web/	[12]
SNPs&GO	Predict using **evolutionary** data, profile and gene ontology (biological process, cellular component and molecular function). When protein function is not available, it run PANTHER and PhD-SNP.	https://snps.biofold.org/snps-and-go/snps-and-go.html	[13]

Table S2. Performance of predictor tools.

Predictor	PPV	NPV	Se	Sp	Ac	MCC	AUC-ROC	Dataset	Ref.
CADD			93.6	57.1	0.85			ClinVar (2015)	[1]
DANN							0.95	ClinVar (2014)	[3]
FATHMM (weighted)	0.85	0.8	0.78	0.87	0.82	0.65		SwissVar (2012)	[4]
MAPP					0.626-0.767			Experimental studies	[5]
Meta-SNP	0.79	0.8	0.8	0.79	0.79	0.59	0.86	SwissVar (2009-2012)	[14]
MutPred2	96		42.3	95.6			84.9	ClinVar32 (2015) and UniProt80 (2015)	[6]
PANTHER-PSEP							0.721	Derived from SwissVar	[7]
PhD-SNPg	0.85	0.85	0.94	0.67	0.85	0.65	0.91	NewClinvar (2016)	[8]
PolyPhen-2*			0.85	0.6015			0.79	Mutations on the genes BRCA1, MSH2, MLH1 and TP53	[15]
PredictSNP					0.642	0.281	0.7	Protein Mutant Database (07Mar26)	[16]
PredictSNP2					0.773	0.55	0.804	Mendelian diseases (multiple databases)	[17]
PROVEAN			0.78	0.79				UniProt human protein	[10]
SNPs&GO	0.83	0.8	0.78	0.85	0.82	0.63		Derived from Swiss-Prot (2008)	[13]
SIFT 4G			0.8	0.735	0.7732	0.53		UniRef90 (2011)	[11]
SNAP2					0.688	0.24		Data set consisting of 9,657 variants from 678 human proteins	[12]
SNP&GO3d	0.84	0.86	0.87	0.83	0.85	0.7	0.92	Derived from Swiss-Prot (2009)	[18]

*Data from an article recommended on the original developer article. PPV, positive predictive value; NPV, negative predictive value; Se, sensibility; Sp, specificity; Ac, accuracy; MCC, Matthews' correlation coefficient test.

23   Table S3..List of the 103 single nucleotide variants (SNVs) on *CYP21A2* gene selected to test the
24   performance of predictor tools. SNVs are grouped into classical (enzyme activity < 10%), non-
25   classical (between 10 and 78 %) and neutral (> 78 %) groups. The enzyme activity levels of both
26   21-hydroxylase substrates - 17-hydroxyprogesterone and progesterone - were obtained from
27   the original paper of the functional characterization. The phenotype was obtained from either
28   the same paper or the original description of the new SNV. [a] Shows the percentage of enzyme
29   activity measured for the conversion of both 21-hydroxylase substrates, considering as 100 %
30   the 21-hydroxylase wild type activity. 17OHP: 17-hydroxyprogesterone. SW: salt wasting. SV:
31   simple-virilizing. NC: non-classical. ND: non-determinate.

Group	NP_000491.4	CYP21A2 Activity *in vitro*				Phenotype	Publication
		17OHP[a]	SD (±)	Progesterone	SD (±)		
CL	p.P31Q	0.2	0.2	0	0	SW	[19]
	p.G57R	0.7	ND	1.4	ND	SV	[20]
	p.G65E	0	ND	0	ND	SW	[21]
	p.I78T	3	2	5	3	SV	[22]
	p.G91V	0	ND	0	ND	SW	[23]
	p.L108R	0.4	ND	0.3	ND	SW	[20]
	p.S114F	4	1	4	2	SV	[24]
	p.L123P	1.42	2.13	-1.86	5.19	SW	[25]
	p.V140E	0.7	1.3	0.5	0.6	SW	[26]
	p.L143P	0.4		0.4		SW	[20]
	p.C148R	4.3	0.9	3.6ny	1.8	SV-NC	[26]
	p.L167P	0.3	0.06	0.4	0.6	SW	[27]
	p.L168P	0.7	ND	0.4	ND	SW	[28]
	p.C170R	0.1	0.02	0	2	SW	[29]
	p.I172N	0.7	0.3	0.6	0.03	SV	[30]
	p.I173N	4.3	1.7	4.4	1.8	SV	[28]
	p.G179R	0.4	0.5	0	0.6	SW	[29]
	p.R234G	8	2	2	1	SV-NC	[31]
	p.I237N	1	0.7	2.4	1.4	SV	[32]
	p.V238E	0	0	0.1	0.3	SW	[32]
	p.V282G	3.9	1.7	3.9	2	SV	[33]
	p.H283N	1.6	6	2.7	5	SW	[34]
	p.G292C	0	ND	0	ND	SW	[23]
	p.G292R	0.5	0.7	0.7	0.2	SW	[26]
	p.G292S	0.8	0.4	0.8	0.4	SW	[35]
	p.G293D	0.5	0.2	0.7	0.4	SW	[28]
	p.L301F	9.5	6.4	4.4	2.5	SV	[33]
	p.W303S	3	0.3	3	0.5	SV-NC	[36]
	p.W303R	0.1	0.2	0	0.5	SW	[29]
	p.L309F	0.2	0.3	0.1	0.3	SW	[26]
	p.E321K	4.6	1.8	4.5	2.6	SV	[28]
	p.R342P	0.7	0.3	0.7	0.2	SV	[30]
	p.R342W	5	0.4	4	3	SV-NC	[31]
	p.E352K	1.1	0.5	1.2	0.3	SV	[37]
	p.R355H	0	ND	0	ND	SW	[23]
	p.R357P	0.15	0.3	0.15	0.3	SW	[38]
	p.R357Q	0.65	0.44	1.1	0.94	SV	[38]
	p.R357W	0	ND	0	ND	SW	[39]
	p.A363V	0	ND	0	ND	SW	[21]
	p.G376S	1.6	0.8	0.7	0.7	SW	[40]
	p.L389R	1.1	0.6	ND	ND	SW	[41]

Continuation (Table S3)

CL	p.H393Q	2.5	0.6	2.2	0.6	SW	[42]
	p.R409C	1.3	0.5			SW	[20]
	p.G425S	1.6	0.4	2	0.6	SV	[28]
	p.R427C	0	0.5	0	0.6	SW	[29]
	p.R427H	0.5	0.6	0.4	0.2	SW-SV	[30]
	p.L447P	0.5	0.6	0	0.1	SW-SV	[30]
	p.T451P	0.9	ND	0.9	ND	SW	[24]
	p.P464L	2.6	0.8	3	0.5	SV	[43]
	p.R484P	1	0.07	2.2	0.9	SV	[35]
	p.R484Q	1.1	0.7	3.8	1.9	SV	[27]
	Mean	**1.52**		**1.32**			
	SD	**2.00**		**1.61**			
NC	p.P31L	13	0.2	2	0.6	NC	[31]
	p.H63L	44.5	ND	20.7	ND	NC	[20]
	p.P106L	62	9	64	12	NC	[44]
	p.H120R	31.6	8	32.5	7	NC	[45]
	p.K122Q	14	5	19.5	4	NC	[46]
	p.R133C	35.4	7.4	15.5	2.7	NC	[47]
	p.E141K	11.3	2.4	ND	ND	SW	[41]
	p.R150C	35.8	14.6	47.3	12.9	NC	[47]
	p.R150P	23.4	1.7	16.9	2	NC	[48]
	p.M151R	17.66	1.87	4.57	1.96	NC	[25]
	p.G179A	19	ND	ND	ND	NC	[23]
	p.Y192H	37.1	7	25.8	9	NC	[34]
	p.I195N	33.2	9	46.7	10	NC	[45]
	p.R225W	51.9	9	45.6	8	NC	[49]
	p.I231T	63.1	22.3	70.6	17	NC	[28]
	p.R234K	15	ND	8.1	ND	SV-NC	[28]
	p.V282L	18	3	18	5	NC	[31]
	p.M284V	16.2	9.3	19	6.8	NC	[47]
	p.V305M	46	18	26	10	NC	[50]
	p.F307V	63.23	5.5	64.17	7.98	SV-NC	[51]
	p.D323G	18	1.2	27	4.7	NC	[36]
	p.R340H	67.1	2.4	45.8	3.7	NC	[52]
	p.V359I	72	7	34	3	NC	[53]
	p.H366N	46.13	4.8	57.77	3.69	NC	[51]
	p.R367C	37	7	28	4	NC	[31]
	p.R370Q	82	6	63	4	NC	[53]
	p.R370W	45.8	1.8	48.5	17.1	NC	[28]
	p.D378Y	81	6	58	4	NC	[53]
	p.E381D	30	ND	ND	ND	SW	[54]
	p.A392T	38.7	9.5	22.9	4.7	NC	[55]
	p.D408N	72.7	7	73.6	10	NC	[49]
	p.E432K	26.2	3.8	24.2	7.4	NC	[47]
	p.A435V	14	2	12	6	SV	[22]
	p.T451M	78	6	43	5	NC	[24]
	p.P454S	38	ND	22.4	3	NC	[31]
	p.L462P	55	8	40	2	NC	[53]
	p.M474I	85	7	66	12	NC	[31]
	p.R480L	75.5	15.7	79.6	12	NC-Normal	[55]
	p.P483S	61	6	54	2	NC	[31]
	Mean	**42.94**		**37.41**			
	SD	**22.59**		**20.98**			

Continuation (Table S3)

Neutral	p.L13M	99	1	100	1	Normal	[24]
	p.A16T	100	0	96	6	Normal- very mildNC	[24]
	p.R17C	95	3	81	3	Normal- very mildNC	[24]
	p.R103K	119.7	22.5	ND	ND	Normal	[41]
	p.A160T	126.6	29.9	ND	ND	Normal	[41]
	p.D184E	100	ND	100	ND	Normal	[56]
	p.S203G	85	2	81	3	Very mild NC	[24]
	p.V212M	99.5	32.4	ND	ND	Normal	[41]
	p.M240K	95.4	24.7	97.7	7.7	Normal	[32]
	p.A266S	90	9	104	15	Normal	[31]
	p.A266V	92	1.4	100	4.3	Normal	[36]
	p.P268L	97	1	87	7	Normal	[24]
	p.S269T	103	15	ND	ND	Normal	[57]
	Average	**100.17**		**94.08**			
	SD	**10.92**		**8.25**			

32

33

34

35 Table S4. Result of 17 predictors for 51 classical single nucleotide variants (SNVs) on the CYP21A2 gene. The classical group has an enzyme activity of < 10% of the
36 wild-type activity. The genomic SNV nomenclature is based on the human chromatin remodeling 38 (Chr38). Del: deleterious; N: Neutral; Pby: Probably; Psb:
37 Possible; B: Benign; Dse: Disease; Efc: Effect; P-Del: Proxy-deleterious; P-N: Proxy-neutral; Dmg: Damaging; T: Tolerated; Ptg: Pathogenic; Csv: Conserved; V:
38 Variable; NR: no result.

Chr38	SNP	Meta-SNP	PredictSNP	PredictSNP2	S3Ds&GO	CADD	ConSurf	DANN	FATHMM	MAPP	MutPred2	PANTHER	PhD-SNPg	PolyPhen2	PROVEAN	SIFT	SNAP2	SNPs&GO
g.32038514C>A	p.P31Q	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	N;
g.32038591G>A	p.G57R	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32038616G>A	p.G65E	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32038752T>C	p.I78T	N	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	N	N	N	N
g.32038791G>T	p.G91V	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039124T>G	p.L108R	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039142C>T	p.S114F	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	B	Pby	Del	Del	Efc	Dse
g.32039169T>C	p.L123P	Dse	Del	N	Dse	P-Del	Csv	Del	T	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039220T>A	p.V140E	Dse	Del	N	Dse	P-Del	Csv	Del	T	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039229T>C	p.L143P	Dse	Del	N	Dse	P-Del	Csv	Del	T	Del	Del	Pby	Ptg	Pby	N	N	N	Dse
g.32039243T>C	p.C148R	N	N	N	N	P-Del	Csv	N	Dmg	Del	Del	Pby	Ptg	Psb	Del	N	N	N
g.32039408T>C	p.L167P	Dse	Del	N	Dse	P-Del	V	Del	T	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039411T>C	p.L168P	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	B	Pby	N	N	N	Dse
g.32039416T>C	p.C170R	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	B	Pby	Del	Del	Efc	Dse
g.32039423T>A	p.I172N	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039426T>A	p.I173N	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse

Continuation (Table S4)

Chr38	SNP	Meta-SNP	PredictSNP	PredictSNP2	S3Ds&GO	CADD	ConSurf	DANN	FATHMM	MAPP	MutPred2	PANTHER	PhD-SNPg	PolyPhen2	PROVEAN	SIFT	SNAP2	SNPs&GO
g.32039443G>A	p.G179R	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039797A>G	p.R234G	Dse	N	N	Dse	P-Del	Csv	Del	T	N	Del	Pby	B	Pby	Del	Del	Efc	Dse
g.32039807T>A	p.I237N	Dse	Del	N	N	P-Del	V	Del	T	Del	Del	Pby	Ptg	Psb	Del	Del	Efc	Dse
g.32039810T>A	p.V238E	Dse	Del	N	Dse	P-Del	Csv	Del	T	Del	Del	Pby	Ptg	Psb	Del	Del	Efc	Dse
g.32040111T>G	p.V282G	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040113C>A	p.H283N	Dse	N	N	Dse	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Pby	Del	Del	N	Dse
g.32040140G>A	p.G292S	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040140G>C	p.G292R	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040140G>T	p.G292C	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040144G>A	p.G293D	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040167C>T	p.L301F	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	N	Del	Pby	B	Pby	Del	Del	Efc	Dse
g.32040173T>C	p.W303R	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040174G>C	p.W303S	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040191C>T	p.L309F	N	N	Del	N	P-Del	Csv	Del	Dmg	N	N	Pby	B	Pby	Del	Del	N	N
g.32040427G>A	p.E321K	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040490C>T	p.R342W	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	N	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040491G>C	p.R342P	Dse	Del	N	Dse	P-Del	Csv	Del	T	Del	Del	Pby	B	Pby	Del	Del	Efc	Dse
g.32040520G>A	p.E352K	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040530G>A	p.R355H	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Psb	Del	Del	Efc	Dse

Continuation (Table S4)

Chr38	SNP	Meta-SNP	PredictSNP	PredictSNP2	S3Ds&GO	CADD	ConSurf	DANN	FATHMM	MAPP	MutPred2	PANTHER	PhD-SNPg	PolyPhen2	PROVEAN	SIFT	SNAP2	SNPs&GO
g.32040535C>T	p.R357W	Dse	Del	N	Dse	P-Del	Csv	Del	T	N	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040536G>A	p.R357Q	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040536G>C	p.R357P	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040554C>T	p.A363V	N	N	N	Dse	P-Del	Csv	Del	T	N	N	Pby	Ptg	Pby	N	N	N	N
g.32040675G>A	p.G376S	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	N	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040715T>G	p.L389R	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040728C>G	p.H393Q	N	N	N	Dse	P-Del	Csv	Del	T	N	Del	Pby	B	B	Del	Del	Efc	N
g.32040871C>T	p.R409C	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Psb	Del	Del	Efc	Dse
g.32040919G>A	p.G425S	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040925C>T	p.R427C	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040926G>A	p.R427H	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040986T>C	p.L447P	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	B	Pby	Del	Del	Efc	Dse
g.32040997A>C	p.T451P	Dse	Del	N	N	P-Del	Csv	Del	T	Del	Del	Pby	Ptg	Psb	Del	Del	N	N
g.32041037C>T	p.P464L	N	N	Del	N	P-Del	Csv	Del	Dmg	Del	N	Pby	Ptg	Pby	Del	Del	N	N
g.32041097G>A	p.R484Q	Dse	Del	Del	N	P-Del	Csv	Del	Dmg	N	Del	Pby	Ptg	Pby	Del	Del	Efc	N
g.32041097G>C	p.R484P	Dse	Del	N	N	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse

39

40

41 Table S5. Result of 17 predictors for 39 non-classical single nucleotide variants (SNVs) on the CYP21A2. The non-classical group has an enzyme activity between
42 >10% and < 78% of the wild-type activity. The genomic SNV nomenclature is based on the human chromatin remodeling 38 (Chr38). Del: deleterious; N: Neutral;
43 Pby: Probably; Psb: Possible; B: Benign; Dse: Disease; Efc: Effect; P-Del: Proxy-deleterious; P-N: Proxy-neutral; Dmg: Damaging; T: Tolerated; Ptg: Pathogenic; Csv:
44 Conserved; V: Variable; NR: no result.

Chr38	SNP	Meta-SNP	PredictSNP	PredictSNP2	S3Ds&GO	CADD	ConSurf	DANN	FATHMM	MAPP	MutPred2	PANTHER	PhD-SNPg	PolyPhen2	PROVEAN	SIFT	SNP2	SNPs&GO
g.32038514C>T	p.P31L	N	N	N	N	P-Del	Csv	N	Dmg	Del	Del	Pby	Ptg	B	N	N	N	N
g.32038610A>T	p.H63L	Dse	N	N	N	P-Del	V	N	T	Del	Del	Pby	B	B	N	N	Efc	N
g.32039118C>T	p.P106L	N	N	N	N	P-N	V	N	T	N	N	Pby	B	B	N	N	Efc	N
g.32039160A>G	p.H120R	N	N	N	N	P-Del	Csv	Del	Dmg	Del	N	Pby	Ptg	Pby	Del	Del	Efc	N
g.32039165A>C	p.K122Q	Dse	Del	N	N	P-Del	Csv	Del	Dmg	Del	N	Pby	Ptg	Pby	Del	Del	Efc	N
g.32039198C>T	p.R133C	Dse	Del	N	Dse	P-Del	V	Del	T	N	N	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039222G>A	p.E141K	N	N	N	N	P-Del	V	Del	T	N	Del	Pby	Ptg	Psb	N	N	N	N
g.32039356C>T	p.R150C	N	N	Del	Dse	P-Del	Csv	Del	Dmg	N	N	Pby	B	Pby	N	N	N	N
g.32039357G>C	p.R150P	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	N	N	N	Dse
g.32039360T>G	p.M151R	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Psb	Del	Del	Efc	Dse
g.32039444G>C	p.G179A	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	N	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32039570T>C	p.Y192H	N	N	N	N	P-N	Csv	N	T	N	N	Pby	B	B	N	N	N	N
g.32039580T>A	p.I195N	N	N	N	Dse	P-Del	Csv	Del	T	N	Del	Pby	Ptg	Pby	N	Del	Efc	Dse
g.32039770C>T	p.R225W	Dse	N	N	N	P-N	V	N	T	N	Del	Pby	B	B	Del	N	N	N
g.32039789T>C	p.I231T	N	N	N	N	P-Del	V	Del	T	N	N	Pby	B	B	N	Del	N	N
g.32039798G>A	p.R234K	N	N	N	Dse	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Pby	N	Del	Efc	N

Continuation (Table S5)

Chr38	SNP	Meta-SNP	PredictSNP	PredictSNP2	S3Ds&GO	CADD	ConSurf	DANN	FATHMM	MAPP	MutPred2	PANTHER	PhD-SNPg	PolyPhen2	PROVEAN	SIFT	SNP2	SNPs&GO
g.32040110G>T	p.V282L	N	N	N	N	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Psb	N	N	N	N
g.32040116A>G	p.M284V	N	N	Del	Dse	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040179G>A	p.V305M	Dse	N	Del	N	P-Del	Csv	Del	Dmg	N	N	Pby	B	Pby	N	Del	N	N
g.32040185T>G	p.F307V	N	N	N	Dse	P-Del	Csv	Del	Dmg	N	Del	Pby	B	Pby	Del	Del	N	Dse
g.32040434A>G	p.D323G	Dse	Del	N	N	P-Del	V	Del	T	Del	Del	Pby	B	Pby	Del	Del	N	N
g.32040485G>A	p.R340H	Dse	Del	Del	N	P-Del	Csv	Del	Dmg	N	Del	Pby	B	Pby	Del	Del	Efc	Dse
g.32040541G>A	p.V359I	N	N	N	N	P-Del	Csv	Del	Dmg	N	N	Pby	B	Psb	N	Del	N	N
g.32040562C>A	p.H366N	Dse	Del	N	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	N
g.32040565C>T	p.R367C	N	N	N	N	P-Del	Csv	Del	T	N	Del	Pby	B	B	N	N	N	N
g.32040574C>T	p.R370W	Dse	Del	N	Dse	P-Del	Csv	Del	T	Del	N	Pby	B	Pby	Del	Del	Efc	Dse
g.32040575G>A	p.R370Q	N	N	N	N	P-Del	Csv	Del	T	N	N	Pby	B	Psb	N	N	N	N
g.32040681G>T	p.D378Y	N	N	N	N	P-Del	Csv	Del	T	N	Del	Pby	B	Psb	Del	N	N	N
g.32040692G>C	p.E381D	N	N	Del	N	P-Del	Csv	Del	Dmg	N	N	Pby	B	B	N	Del	Efc	N
g.32040723G>A	p.A392T	N	N	Del	Dse	P-Del	Csv	Del	Dmg	Del	N	Pby	B	Pby	N	N	N	Dse
g.32040771G>A	p.D408N	N	N	Del	N	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Pby	N	Del	N	N
g.32040940G>A	p.E432K	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	N	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040950C>T	p.A435V	Dse	Del	Del	Dse	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	Efc	Dse
g.32040998C>T	p.T451M	N	Del	N	N	P-Del	Csv	Del	T	Del	N	Pby	Ptg	Psb	Del	Del	N	N
g.32041006C>T	p.P454S	N	Del	Del	N	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Pby	Del	Del	N	N

Continuation (Table S5)

Chr38	SNP	Meta-SNP	PredictSNP	PredictSNP2	S3Ds&GO	CADD	ConSurf	DANN	FATHMM	MAPP	MutPred2	PANTHER	PhD-SNPg	PolyPhen2	PROVEAN	SIFT	SNP2	SNPs&GO
g.32041031T>C	p.L462P	Dse	Del	Del	N	P-Del	Csv	Del	Dmg	Del	Del	Pby	Ptg	Pby	Del	Del	N	N
g.32041068G>T	p.M474I	N	N	N	N	P-N	V	N	T	N	N	Pby	B	B	Del	N	N	N
g.32041085G>T	p.R480L	N	N	N	N	P-Del	V	Del	T	N	N	Pby	B	B	N	N	N	N
g.32041093C>T	p.P483S	N	N	Del	N	P-Del	Csv	Del	Dmg	N	N	Pby	Ptg	Pby	N	Del	Efc	N

45

46

47 Table S6. Result of 17 predictors for 13 neutral single nucleotide variants (SNVs) on the CYP21A2 gene. The neutral group has the enzyme activity known as > 78%
48 of the wild-type activity. The genomic SNV nomenclature is based on the human chromatin remodeling 38 (Chr38). Del: deleterious; N: Neutral; Pby: Probably;
49 Psb: Possible; Dse: Disease; Efc: Effect; P-Del: Proxy-deleterious; P-N: Proxy-neutral; Dmg: Damaging; T: Tolerated; Ptg: Pathogenic; B: Benign; Csv: Conserved; V:
50 Variable; NR: no result.

Chr38	SNP	Meta-SNP	PredictSNP	PredictSNP2	S3Ds&GO	CADD	ConSurf	DANN	FATHMM	MAPP	MutPred2	PANTHER	PhD-SNPg	PolyPhen2	PROVEAN	SIFT	SNP2	SNPs&GO
g.32038459C>A	p.L13M	N	N	N	NR	P-Del	NR	Del	T	Del	N	NR	B	Pby	N	Del	N	N
g.32038468G>A	p.A16T	N	N	N	NR	P-N	NR	N	T	N	N	NR	B	B	N	N	N	N
g.32038471C>T	p.R17C	N	N	N	NR	P-N	NR	Del	T	N	N	NR	B	B	N	Del	N	N
g.32039109G>A	p.R103K	N	N	N	N	P-N	V	N	T	N	N	NR	B	B	N	N	N	N
g.32039386G>A	p.A160T	N	N	N	N	P-N	Csv	N	T	N	N	Pby	B	B	N	N	N	N
g.32039548C>G	p.D184E	N	N	N	N	P-N	V	N	T	N	N	Pby	B	B	N	N	N	N
g.32039603A>G	p.S203G	N	N	N	N	P-N	V	N	T	N	N	Pby	B	B	N	N	N	N
g.32039630G>A	p.V212M	N	N	N	N	P-N	V	Del	T	N	N	Pby	B	B	N	N	N	N
g.32039816T>A	p.M240K	N	N	N	N	P-Del	V	N	T	N	N	Pby	Ptg	B	N	N	N	N
g.32040062G>T	p.A266S	N	N	N	N	P-N	V	N	T	N	N	Pby	B	B	N	N	N	N
g.32040063C>T	p.A266V	N	N	N	N	P-N	V	Del	T	Del	N	Pby	B	B	N	N	N	N
g.32040069C>T	p.P268L	N	N	N	NR	P-N	V	N	T	N	N	Pby	B	B	N	N	N	N
g.32040072G>C	p.S269T	N	N	N	NR	P-N	V	N	T	NR	N	Pby	B	B	N	N	N	N

51

52

Reference

1. van der Velde, K.J.; de Boer, E.N.; van Diemen, C.C.; Sikkema-Raddatz, B.; Abbott, K.M.; Knopperts, A.; Franke, L.; Sijmons, R.H.; de Koning, T.J.; Wijmenga, C.; et al. GAVIN: Gene-Aware Variant INterpretation for Medical Sequencing. *Genome Biology* **2017**, *18*, doi:10.1186/s13059-016-1141-7.

2. Ashkenazy, H.; Abadi, S.; Martz, E.; Chay, O.; Mayrose, I.; Pupko, T.; Ben-Tal, N. ConSurf 2016: An Improved Methodology to Estimate and Visualize Evolutionary Conservation in Macromolecules. *Nucleic Acids Research* **2016**, *44*, W344–W350, doi:10.1093/nar/gkw408.

3. Quang, D.; Chen, Y.; Xie, X. DANN: A Deep Learning Approach for Annotating the Pathogenicity of Genetic Variants. *Bioinformatics* **2015**, *31*, 761–763, doi:10.1093/bioinformatics/btu703.

4. Shihab, H.A.; Gough, J.; Cooper, D.N.; Stenson, P.D.; Barker, G.L.A.; Edwards, K.J.; Day, I.N.M.; Gaunt, T.R. Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions Using Hidden Markov Models. *Human Mutation* **2013**, *34*, 57–65, doi:10.1002/humu.22225.

5. Stone, E.A.; Sidow, A. Physicochemical Constraint Violation by Missense Substitutions Mediates Impairment of Protein Function and Disease Severity. *Genome Research* **2005**, *15*, 978–986, doi:10.1101/gr.3804205.

6. Pejaver, V.; Urresti, J.; Lugo-Martinez, J.; Pagel, K.A.; Lin, G.N.; Nam, H.J.; Mort, M.; Cooper, D.N.; Sebat, J.; Iakoucheva, L.M.; et al. Inferring the Molecular and Phenotypic Impact of Amino Acid Variants with MutPred2. *Nature Communications* **2020**, *11*, doi:10.1038/s41467-020-19669-x.

7. Tang, H.; Thomas, P.D. PANTHER-PSEP: Predicting Disease-Causing Genetic Variants Using Position-Specific Evolutionary Preservation. *Bioinformatics* **2016**, *32*, 2230–2232, doi:10.1093/bioinformatics/btw222.

8. Capriotti, E.; Fariselli, P. PhD-SNPg: A Webserver and Lightweight Tool for Scoring Single Nucleotide Variants. *Nucleic Acids Research* **2017**, *45*, W247–W252, doi:10.1093/nar/gkx369.

9. Adzhubei, I.; Jordan, D.M.; Sunyaev, S.R. Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. *Current Protocols in Human Genetics* **2013**, *76*, doi:10.1002/0471142905.hg0720s76.

10. Choi, Y.; Sims, G.E.; Murphy, S.; Miller, J.R.; Chan, A.P. Predicting the Functional Effect of Amino Acid Substitutions and Indels. *PLoS ONE* **2012**, *7*, doi:10.1371/journal.pone.0046688.

11. Vaser, R.; Adusumalli, S.; Leng, S.N.; Sikic, M.; Ng, P.C. SIFT Missense Predictions for Genomes. *Nature Protocols* **2016**, *11*, 1–9, doi:10.1038/nprot.2015.123.

12. Hecht, M.; Bromberg, Y.; Rost, B. Better Prediction of Functional Effects for Sequence Variants. *BMC Genomics* **2015**, *16*, doi:10.1186/1471-2164-16-S8-S1.

13. Calabrese, R.; Capriotti, E.; Fariselli, P.; Martelli, P.L.; Casadio, R. Functional Annotations Improve the Predictive Score of Human Disease-Related Mutations in Proteins. *Human Mutation* **2009**, *30*, 1237–1244, doi:10.1002/humu.21047.

95   14.   Capriotti, E.; Altman, R.B.; Bromberg, Y. Collective Judgment Predicts Disease-
96   Associated Single Nucleotide Variants. *BMC genomics* **2013**, *14 Suppl 3*,
97   doi:10.1186/1471-2164-14-s3-s2.

98   15.   Hicks, S.; Wheeler, D.A.; Plon, S.E.; Kimmel, M. Prediction of Missense Mutation
99   Functionality Depends on Both the Algorithm and Sequence Alignment Employed.
100   *Human Mutation* **2011**, *32*, 661–668, doi:10.1002/humu.21490.

101   16.   Bendl, J.; Stourac, J.; Salanda, O.; Pavelka, A.; Wieben, E.D.; Zendulka, J.; Brezovsky, J.;
102   Damborsky, J. PredictSNP: Robust and Accurate Consensus Classifier for Prediction of
103   Disease-Related Mutations. *PLoS Computational Biology* **2014**, *10*,
104   doi:10.1371/journal.pcbi.1003440.

105   17.   Bendl, J.; Musil, M.; Štourač, J.; Zendulka, J.; Damborský, J.; Brezovský, J. PredictSNP2: A
106   Unified Platform for Accurately Evaluating SNP Effects by Exploiting the Different
107   Characteristics of Variants in Distinct Genomic Regions. *PLoS Computational Biology*
108   **2016**, *12*, doi:10.1371/journal.pcbi.1004962.

109   18.   Capriotti, E.; Altman, R.B. Improving the Prediction of Disease-Related Variants Using
110   Protein Three-Dimensional Structure. *BMC Bioinformatics* **2011**, *12*, doi:10.1186/1471-
111   2105-12-S4-S3.

112   19.   Lajic, S.; Nikoshkov, A.; Holst, M.; Wedell, A. *Effects of Missense Mutations and*
113   *Deletions on Membrane Anchoring and Enzyme Function of Human Steroid 21-*
114   *Hydroxylase (P450c21)*; 1999;

115   20.   Soardi, F.C.; Barbaro, M.; Lau, I.F.; Lemos-Marini, S.H. v.; Baptista, M.T.M.; Guerra-
116   Junior, G.; Wedell, A.; Lajic, S.; de Mello, M.P. Inhibition of CYP21A2 Enzyme Activity
117   Caused by Novel Missense Mutations Identified in Brazilian and Scandinavian Patients.
118   *The Journal of Clinical Endocrinology & Metabolism* **2008**, *93*, 2416–2420,
119   doi:10.1210/jc.2007-2594.

120   21.   Ohlsson, G.; Muller, J.; Skakkebaek, N.E.; Schwartz, M. Steroid 21-Hydroxylase
121   Deficiency: Mutational Spectrum in Denmark, Three Novel Mutations, and in Vitro
122   Expression Analysis. *Human Mutation* **1999**, *13*, 482–486, doi:10.1002/(SICI)1098-
123   1004(1999)13:6<482::AID-HUMU8>3.0.CO;2-0.

124   22.   Krone, N.; Riepe, F.G.; Grötzinger, J.; Partsch, C.-J.; Sippell, W.G. Functional
125   Characterization of Two Novel Point Mutations in the *CYP21* Gene Causing Simple
126   Virilizing Forms of Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
127   *The Journal of Clinical Endocrinology & Metabolism* **2005**, *90*, 445–454,
128   doi:10.1210/jc.2004-0813.

129   23.   Nunez, B.S.; Lobato, M.N.; White, P.C.; Meseguer, A. Functional Analysis of Four CYP21
130   Mutations from Spanish Patients with Congenital Adrenal Hyperplasia. *Biochemical and*
131   *Biophysical Research Communications* **1999**, *262*, 635–637,
132   doi:10.1006/bbrc.1999.1271.

133   24.   de Paula Michelatto, D.; Karlsson, L.; Lusa, A.L.G.; Silva, C.D.M.; Östberg, L.J.; Persson,
134   B.; Guerra-Júnior, G.; Lemos-Marini, S.H.V. de; Barbaro, M.; de Mello, M.P.; et al.
135   Functional and Structural Consequences of Nine *CYP21A2* Mutations Ranging from Very
136   Mild to Severe Effects. *International Journal of Endocrinology* **2016**, *2016*, 1–10,
137   doi:10.1155/2016/4209670.

138 25. Massimi, A.; Malaponti, M.; Federici, L.; Vinciguerra, D.; Manca Bitti, M.; Vottero, A.;
139   Ghizzoni, L.; Maccarrone, M.; Cappa, M.; Bernardini, S.; et al. Functional and Structural
140   Analysis of Four Novel Mutations of CYP21A2 Gene in Italian Patients with 21-
141   Hydroxylase Deficiency. *Hormone and Metabolic Research* **2014**, *46*, 515–520,
142   doi:10.1055/s-0034-1371864.

143 26. Barbaro, M.; Soardi, F.C.; Palandi de Mello, M.; Wedell, A.; Lajic, S. Functional Studies of
144   CYP21A2 Mutants Complement Structural and Clinical Predictions of Disease Severity in
145   CAH. *Clinical Endocrinology* **2012**, *76*, 766–768, doi:10.1111/j.1365-2265.2011.04275.x.

146 27. Robins, T.; Bellanne-Chantelot, C.; Barbaro, M.; Cabrol, S.; Wedell, A.; Lajic, S.
147   Characterization of Novel Missense Mutations in CYP21 Causing Congenital Adrenal
148   Hyperplasia. *Journal of Molecular Medicine* **2007**, *85*, 247–255, doi:10.1007/s00109-
149   006-0121-x.

150 28. Tardy, V.; Menassa, R.; Sulmont, V.; Lienhardt-Roussie, A.; Lecointre, C.; Brauner, R.;
151   David, M.; Morel, Y. Phenotype-Genotype Correlations of 13 Rare CYP21A2 Mutations
152   Detected in 46 Patients Affected with 21-Hydroxylase Deficiency and in One Carrier.
153   *Journal of Clinical Endocrinology and Metabolism* **2010**, *95*, 1288–1300,
154   doi:10.1210/jc.2009-1202.

155 29. Grischuk, Y.; Rubtsov, P.; Riepe, F.G.; Grötzinger, J.; Beljelarskaia, S.; Prassolov, V.;
156   Kalintchenko, N.; Semitcheva, T.; Peterkova, V.; Tiulpakov, A.; et al. Four Novel
157   Missense Mutations in the CYP21A2 Gene Detected in Russian Patients Suffering from
158   the Classical Form of Congenital Adrenal Hyperplasia: Identification, Functional
159   Characterization, and Structural Analysis. *The Journal of Clinical Endocrinology &*
160   *Metabolism* **2006**, *91*, 4976–4980, doi:10.1210/jc.2006-0777.

161 30. Barbaro, M.; Baldazzi, L.; Balsamo, A.; Lajic, S.; Robins, T.; Barp, L.; Pirazzoli, P.; Cacciari,
162   E.; Cicognani, A.; Wedell, A. Functional Studies of Two Novel and Two Rare Mutations in
163   the 21-Hydroxylase Gene. *Journal of Molecular Medicine* **2006**, *84*, 521–528,
164   doi:10.1007/s00109-006-0043-7.

165 31. Barbaro, M.; Soardi, F.C.; Östberg, L.J.; Persson, B.; de Mello, M.P.; Wedell, A.; Lajic, S.
166   In Vitro Functional Studies of Rare CYP21A2 Mutations and Establishment of an Activity
167   Gradient for Nonclassic Mutations Improve Phenotype Predictions in Congenital
168   Adrenal Hyperplasia. *Clinical Endocrinology* **2015**, *82*, 37–44, doi:10.1111/cen.12526.

169 32. Robins, T.; Barbaro, M.; Lajic, S.; Wedell, A. Not All Amino Acid Substitutions of the
170   Common Cluster E6 Mutation in CYP21 Cause Congenital Adrenal Hyperplasia. *The*
171   *Journal of Clinical Endocrinology & Metabolism* **2005**, *90*, 2148–2153,
172   doi:10.1210/jc.2004-1937.

173 33. Lajić, S.; Robins, T.; Krone, N.; Schwarz, H.P.; Wedell, A. CYP21 Mutations in Simple
174   Virilizing Congenital Adrenal Hyperplasia. *Journal of Molecular Medicine* **2001**, *79*, 581–
175   586, doi:10.1007/s001090100261.

176 34. Concolino, P.; Mello, E.; Patrosso, M.C.; Penco, S.; Zuppi, C.; Capoluongo, E. P.H282N
177   and p.Y191H: 2 Novel CYP21A2 Mutations in Italian Congenital Adrenal Hyperplasia
178   Patients. *Metabolism* **2012**, *61*, 519–524, doi:10.1016/j.metabol.2011.08.008.

179 35. Nikoshkov, A.; Lajic, S.; Vlamis-Gardikas, A.; Tranebjærg, L.; Holst, M.; Wedell, A.;
180   Luthman, H. Naturally Occurring Mutants of Human Steroid 21-Hydroxylase (P450c21)

181   Pinpoint Residues Important for Enzyme Activity and Stability. *Journal of Biological*
182   *Chemistry* **1998**, *273*, 6163–6165, doi:10.1074/jbc.273.11.6163.

183 36. Bleicken, C.; Loidi, L.; Dhir, V.; Parajes, S.; Quinteiro, C.; Dominguez, F.; Grötzinger, J.;
184   Sippell, W.G.; Riepe, F.G.; Arlt, W.; et al. Functional Characterization of Three CYP21A2
185   Sequence Variants (p.A265V, p.W302S, p.D322G) Employing a Yeast Co-Expression
186   System. *Human Mutation* **2009**, *30*, E443–E450, doi:10.1002/humu.20926.

187 37. Krone, N.; Riepe, F.G.; Grötzinger, J.; Partsch, C.-J.; Brämswig, J.; Sippell, W.G. The
188   Residue E351 Is Essential for the Activity of Human 21-Hydroxylase: Evidence from a
189   Naturally Occurring Novel Point Mutation Compared with Artificial Mutants Generated
190   by Single Amino Acid Substitutions. *Journal of Molecular Medicine* **2005**, *83*, 561–568,
191   doi:10.1007/s00109-005-0655-3.

192 38. Lajic, S.; Levo, A.; Nikoshkov, A.; Lundberg, Y.; Partanen, J.; Wedell, A. A Cluster of
193   Missense Mutations at Arg356 of Human Steroid 21-Hydroxylase May Impair Redox
194   Partner Interaction. *Human Genetics* **1997**, *99*, 704–709, doi:10.1007/s004390050436.

195 39. Chiou, S.H.; Hu, M.C.; CHung, B. A Missense Mutation of Ile172 → Asn or Arg356 → Trp
196   Causes Steroid 21-Hydroxylase Deficiency. *Journal of Biological Chemistry* **1990**, *265*,
197   3549–3552, doi:10.1016/s0021-9258(19)39804-7.

198 40. Lajić, S.; Clauin, S.; Robins, T.; Vexiau, P.; Blanché, H.; Bellanne-Chantelot, C.; Wedell, A.
199   Novel Mutations in CYP21 Detected in Individuals with Hyperandrogenism. *The Journal*
200   *of Clinical Endocrinology & Metabolism* **2002**, *87*, 2824–2829,
201   doi:10.1210/jcem.87.6.8525.

202 41. Brønstad, I.; Breivik, L.; Methlie, P.; Wolff, A.S.B.; Bratland, E.; Nermoen, I.; Løvås, K.;
203   Husebye, E.S. Functional Studies of Novel CYP21A2 Mutations Detected in Norwegian
204   Patients with Congenital Adrenal Hyperplasia. *Endocrine Connections* **2014**, *3*, 67–74,
205   doi:10.1530/ec-14-0032.

206 42. Xu, C.; Jia, W.; Cheng, X.; Ying, H.; Chen, J.; Xu, J.; Guan, Q.; Zhou, X.; Zheng, D.; Li, G.; et
207   al. Genotype–Phenotype Correlation Study and Mutational and Hormonal Analysis in a
208   Chinese Cohort with 21-hydroxylase Deficiency. *Molecular Genetics & Genomic*
209   *Medicine* **2019**, *7*, doi:10.1002/mgg3.671.

210 43. Krone, N.; Riepe, F.; Partsch, C.-J.; Vorhoff, W.; Brämswig, J.; Sippell, W. Three Novel
211   Point Mutations of the CYP21 Gene Detected in Classical Forms of Congenital Adrenal
212   Hyperplasia Due to 21-Hydroxylase Deficiency. *Experimental and Clinical Endocrinology*
213   *& Diabetes* **2006**, *114*, 111–117, doi:10.1055/s-2005-872841.

214 44. Nikoshkov, A.; Lajic, S.; Holst, M.; Wedell, A.; Luthman, H. Synergistic Effect of Partially
215   Inactivating Mutations in Steroid 21-Hydroxylase Deficiency [1]. *The Journal of Clinical*
216   *Endocrinology & Metabolism* **1997**, *82*, 194–199, doi:10.1210/jcem.82.1.3678.

217 45. Concolino, P.; Vendittelli, F.; Mello, E.; Alinovi, C.C.; Minucci, A.; Carrozza, C.; Santini,
218   S.A.; Zuppi, C.; Capoluongo, E. Two Novel CYP21A2 Missense Mutations in Italian
219   Patients with 21-Hydroxylase Deficiency: Identification and Functional Characterisation.
220   *IUBMB Life* **2009**, *61*, 229–235, doi:10.1002/iub.147.

221 46. Riepe, F.G.; Hiort, O.; Grötzinger, J.; Sippell, W.G.; Krone, N.; Holterhus, P.-M.
222   Functional and Structural Consequences of a Novel Point Mutation in the *CYP21A2*
223   Gene Causing Congenital Adrenal Hyperplasia: Potential Relevance of Helix C for P450

224   Oxidoreductase-21-Hydroxylase Interaction. *The Journal of Clinical Endocrinology &*
225   *Metabolism* **2008**, *93*, 2891–2895, doi:10.1210/jc.2007-2646.

226 47. Taboas, M.; Gómez Acuña, L.; Scaia, M.F.; Bruque, C.D.; Buzzalino, N.; Stivel, M.;
227   Ceballos, N.R.; Dain, L. Functional Studies of p.R132C, p.R149C, p.M283V, p.E431K, and
228   a Novel c.652-2A>G Mutations of the CYP21A2 Gene. *PLoS ONE* **2014**, *9*, e92181,
229   doi:10.1371/journal.pone.0092181.

230 48. Chu, X.; Ding, H.; Cui, G.; Xu, Y.; Wang, D.W.; He, Y. Functional Consequences of a Novel
231   Point Mutation in the CYP21A2 Gene Identified in a Chinese Han Patient with
232   Nonclassic 21-Hydroxylase Deficiency. *Clinical Endocrinology* **2014**, *80*, 927–928,
233   doi:10.1111/cen.12309.

234 49. Concolino, P.; Vendittelli, F.; Mello, E.; Minucci, A.; Carrozza, C.; Rossodivita, A.;
235   Giardina, B.; Zuppi, C.; Capoluongo, E. Functional Analysis of Two Rare CYP21A2
236   Mutations Detected in Italian Patients with a Mildest Form of Congenital Adrenal
237   Hyperplasia. *Clinical Endocrinology* **2009**, *71*, 470–476, doi:10.1111/j.1365-
238   2265.2008.03517.x.

239 50. Lajić, S.; Clauin, S.; Robins, T.; Vexiau, P.; Blanché, H.; Bellanne-Chantelot, C.; Wedell, A.
240   Novel Mutations in CYP21 Detected in Individuals with Hyperandrogenism. *The Journal*
241   *of Clinical Endocrinology & Metabolism* **2002**, *87*, 2824–2829,
242   doi:10.1210/jcem.87.6.8525.

243 51. Khajuria, R.; Walia, R.; Bhansali, A.; Prasad, R. Functional Characterization and
244   Molecular Modeling of the Mutations in CYP21A2 Gene from Patients with Congenital
245   Adrenal Hyperplasia. *Biochimie* **2018**, *149*, 115–121, doi:10.1016/j.biochi.2018.04.012.

246 52. Helmberg, A.; Tusie-Luna, M.T.; Tabarelli, M.; Kofler, R.; White, P.C. R339H and P453S:
247   CYP21 Mutations Associated with Nonclassic Steroid 21-Hydroxylase Deficiency That
248   Are Not Apparent Gene Conversions. *Molecular Endocrinology* **1992**, *6*, 1318–1322,
249   doi:10.1210/mend.6.8.1406709.

250 53. Karlsson, L.; de Paula Michelatto, D.; Lusa, A.L.G.; D'Almeida Mgnani Silva, C.; Östberg,
251   L.J.; Persson, B.; Guerra-Júnior, G.; Valente de Lemos-Marini, S.H.; Baldazzi, L.; Menabó,
252   S.; et al. Novel Non-Classic CYP21A2 Variants, Including Combined Alleles, Identified in
253   Patients with Congenital Adrenal Hyperplasia. *Clinical Biochemistry* **2019**, *73*, 50–56,
254   doi:10.1016/j.clinbiochem.2019.07.009.

255 54. Hsu, N.-C.; Guzov, V.M.; Hsu, L.-C.; Chung, B. Characterization of the Consequence of a
256   Novel Glu-380 to Asp Mutation by Expression of Functional P450c21 in Escherichia Coli.
257   *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology*
258   **1999**, *1430*, 95–102, doi:10.1016/S0167-4838(98)00271-4.

259 55. Robins, T.; Bellanne-Chantelot, C.; Barbaro, M.; Cabrol, S.; Wedell, A.; Lajic, S.
260   Characterization of Novel Missense Mutations in CYP21 Causing Congenital Adrenal
261   Hyperplasia. *Journal of Molecular Medicine* **2007**, *85*, 247–255, doi:10.1007/s00109-
262   006-0121-x.

263 56. Higashi, Y.; Hiromasa, T.; Tanae, A.; Miki, T.; Nakura, J.; Kondo, T.; Ohura, T.; Ogawa, E.;
264   Nakayama, K.; Fujii-Kuriyama, Y. Effects of Individual Mutations in the P-450(C21)
265   Pseudogene on the P-450(C21) Activity and Their Distribution in the Patient Genomes
266   of Congenital Steroid 21-Hydroxylase Deficiency1. *The Journal of Biochemistry* **1991**,
267   *109*, 638–644, doi:10.1093/oxfordjournals.jbchem.a123433.

268   57.   Wu, D.A.; Chung, B.C. Mutations of P450c21 (Steroid 21-Hydroxylase) at Cys428,
269   Val281, and Ser268 Result in Complete, Partial, or No Loss of Enzymatic Activity,
270   Respectively. *Journal of Clinical Investigation* **1991**, *88*, 519–523,
271   doi:10.1172/JCI115334.

272